Introduction
============

Polychlorinated biphenyls (PCBs) are a group of structurally related organic compounds that, because of their inertness and thermal stability, have been extensively used in various industrial and commercial applications. Although manufacturing of PCBs was banned in the late 1970s due to concerns of possible adverse effects in humans, these compounds still persist in the environment ([@r9]). Similar concerns in the 1970s also led to ban or severe restrictions on the use of the organochlorine pesticides hexachlorobenzene (HCB) and dichlorodiphenyltrichloroethane (*p,p*´-DDT). Because of their lipophilic and persistent nature, *p,p*´-DDT and its metabolite dichlorodiphenyldichloroethylene (*p,p*´-DDE), HCB, and PCBs accumulate through the food chain, with seafood currently being the main route of human exposure ([@r15]; [@r45]). On entering the human body, these compounds dissolve in lipids but they can also bind to proteins in blood ([@r29]), and during pregnancy they are readily transported across the placenta ([@r7]; [@r35]).

There is some evidence to suggest that prenatal exposure to PCBs may adversely affect development and maturation of the immune system ([@r24]). Studies focusing on background prenatal exposures to PCBs have reported associations with increased respiratory and otitis media infections ([@r8]; [@r13]; [@r49]), altered immune cell counts ([@r13]; [@r21]; [@r49]), and reduced antibody responses to childhood vaccines ([@r18]; [@r49]). Reports on atopic diseases such as asthma and wheeze have been divergent, with two studies reporting positive associations ([@r14]; [@r42]) and another reporting an inverse association ([@r49], [@r50]). At least two studies have reported positive associations between prenatal exposures to *p,p*´-DDE and asthma in offspring at 4--9 years of age ([@r22]; [@r43]), whereas evidence for immunological effects of HCB has mostly been obtained from animal studies ([@r10]; [@r26]).

Divergent findings on associations between prenatal exposures to these persistent organochlorine pollutants (POPs) and asthma may relate to the fact that most studies have not had follow-up beyond 6--7 years of age, which would facilitate more accurate diagnoses of permanent asthma when coughing and wheeze symptoms have stabilized. Divergent findings may also relate to differences in relative and absolute concentrations of different organochlorine compounds across studies due to temporal and regional differences ([@r23]). Furthermore, previous studies have mostly relied on self- or parental report to assess asthma, which may be prone to misclassification ([@r37], [@r38]).

The aim of this study was to investigate the association between maternal serum concentrations of PCBs, HCB, and *p,p*´-DDE in a cohort of environmentally exposed Danish pregnant women and risk of asthma in offspring after 20 years of follow-up.

Methods
=======

*Study population*. In Aarhus, Denmark, the Danish Fetal Origins 1988--1989 Cohort was formed and included 965 (80%) of 1,212 eligible women with singleton pregnancies who attended a large prenatal clinic during the study period. The cohort has been described in detail elsewhere ([@r33]). Briefly, the data collection included a self-administered dietary questionnaire that was sent to the women 1 week before their scheduled 30th week antenatal visit. During the midwife visit the women participated in a face-to-face interview and gave information about diet, lifestyle, anthropometry, medical history, and socioeconomic status. A blood sample was collected and immediately separated into erythrocytes, serum, and plasma, and was frozen at --20 °C. Information about the health of the mothers and birth outcomes was collected from the Danish Medical Birth Registry (Copenhagen, Denmark).

*Follow-up of children*. In 2008 a follow-up study was conducted including the offspring whose mothers were originally enrolled. Health information was obtained from the Danish population-based disease registries, and the offspring were also contacted and asked to complete a self-administered web-based questionnaire covering anthropometry, lifestyle, diet, and health. The questionnaire included standardized questions on asthma from the International Study of Asthma and Allergies in Childhood (ISAAC) ([@r1]).

The study was approved by the Danish Data Protection Agency and the Danish Council of Ethics (Reference No. 20070157), and all participants gave written consent before inclusion in the study.

*Exposure measures*. A total of six PCBs (congeners 118, 138, 153, 156, 170, and 180), *p,p*´-DDE, and HCB were measured in 200-μL aliquots from archived maternal serum using an extension of previously published methods ([@r39]) described in more detail elsewhere ([@r5]). In each batch of samples (*n* = 25), two blanks were included to control for possible laboratory contamination, in addition to two positive control samples. Average recoveries of measured POPs in the control samples were 97--106% of the certified values. The between-assay coefficient of variation was 4.0% (at 0.17 ng/mL) for PCB-118; 2.7% (at 0.94 ng/mL) for PCB-153; 4.0% (at 0.08 ng/mL) for HCB; and 2.1% (at 11.5 ng/mL) for *p,p*´-DDE. The limits of quantification (LOQs) for the PCBs and *p,p*´-DDE were 2--5 pg/mL. The LOQ for HCB was 25 pg/mL. The concentrations of the six PCB congeners, *p,p*´-DDE, and HCB were above the LOQs in all samples.

*Outcome measures*. Participants were classified as asthma cases using a previously validated definition based on medication data ([@r30]). We used Danish personal identification numbers to link each participant to the Registry of Medicinal Product Statistics (RMPS; Copenhagen, Denmark), which has collected information about all prescriptions redeemed in Danish pharmacies since 1995, and extracted information about all medications used to treat asthma \[Anatomical Therapeutic Chemical Classification System (ATC; World Health Organization, Oslo, Norway) codes R03A, R03B, R03C, and R03D\].

Participants who were prescribed medication(s) used for the treatment of asthma from 6 to 20 years of age were classified as cases, except for those who received prescriptions for liquid β2-agonists only, or who received only one prescription for an inhaled β2-agonist or an inhaled steroid ([@r30]). The date when an offspring became an asthma case for the first time was used in the analyses. As secondary outcome measures, we used three additional asthma definitions. Self-reported lifetime doctor diagnosis of asthma was assessed from a standardized ISAAC question on the follow-up questionnaire at 20 years of age and defined as offspring with a positive answer to this question. Offspring with a self-reported doctor diagnosis were furthermore asked if they had used any asthma medications in the previous 12 months, to define self-reported current use of asthma medications. We also used hospital diagnoses for asthma from the mandatory Danish National Patient Register (DNPR; Copenhagen, Denmark), which contains information about all hospital admissions in Denmark since 1977 and emergency department and outpatient contacts since 1995. We defined a hospital asthma case as offspring with any asthma diagnosis (including hospital in-, out-, and emergency department patients) by the *International Classification of Diseases, 10th Revision* (ICD-10; National Board of Health, Denmark 1994) codes J45.0, J45.1, J45.2, J45.8, J45.9 J46.9, and *8th Revision* (ICD-8; National Board of Health, Denmark 1977) codes 493.00, 493.01, 493.02, 493.08, 493.09) from birth to 20 years of age. We used the date of the first hospital diagnosis in the analyses.

*Mother--child pairs available for analysis*. For the 965 women originally enrolled in the study, a sufficient amount of serum from week 30 of gestation was available for 872 subjects (90%). These women and their offspring form the basis for this study. There were no major differences in baseline characteristics between participants and nonparticipants (*n* = 93) (data not shown). Information on use of medication (from 1995, offspring ≈ 6 years of age) and hospital diagnosis (from birth) were available for all offspring. Self-reported lifetime diagnosis of asthma and self-reported medication use in the preceding 12 months were available for 654 offspring who filled out the web-based questionnaire at the 2008 follow-up.

*Statistical analyses*. We used the median and 10th and 90th percentiles to describe skewed variables, the mean ± SD for normal variables, and percentages for categorical variables. The dioxin-like PCBs (congeners 118 and 156) and the non-dioxin-like PCBs (congeners 138, 153, 170, and 180) and the sum of all six congeners were analyzed separately and aggregated on the bases of molar concentrations. Otherwise, wet-weight concentrations (nanograms per milliliter) were used for individual PCB congeners, HCB, and *p,p*´-DDE. In our primary analysis we examined the association between maternal PCB, HCB, and *p,p*´-DDE serum concentrations and offspring risk of asthma (based on asthma medication use) during 20 years of follow-up using Cox regression models. Maternal concentrations of the organochlorine compounds were divided into tertiles, and hazard ratios (HRs) and 95% CIs were calculated using age as the underlying time scale. Participants were thus considered at risk of asthma from their age at the start of follow-up in 1995, until time of becoming an asthma case (based on asthma use) or the defined end of follow-up (end of 2008), whichever came first. None of the participants were censored for other reasons, such as death or emigration. Using this model we assumed that all offspring were free of asthma at the start of follow-up in 1995, when the offspring were around 6 years of age. Any prescription of asthma medication before 1995 was assumed to be related to coughing and wheezing rather than asthma ([@r19]). Visual inspection of cumulative residual plots did not indicate violations to the assumption of proportional hazards (data not shown). When examining associations between maternal concentrations of POPs and offspring asthma, we performed trend tests by assigning the median concentration to each exposure level (tertile) and included this in the regression models as a continuous variable.

To test the stability of our findings, both with respect to the asthma definition and the assumption that offspring were disease free until 6 years of age, we also estimated associations of PCB, HCB, and *p,p*´-DDE with first asthma diagnosis in the DNPR from birth to 20 years of age using Cox regression. Furthermore, we examined the relation between PCB, HCB, and *p,p*´-DDE, self-reported lifetime diagnosis of asthma, and self-reported current use of asthma medication using logistic regression.

Information on covariates was obtained from questionnaires completed by the mothers during pregnancy and from maternal birth records, and the following covariates were included as adjustment factors in the multivariate models: maternal age (continuous), parity (0, 1, ≥ 2), prepregnancy body mass index (BMI; kilograms per meter squared) (\< 18.5, 18.5 to \< 25, 25 to \< 30, ≥ 30), maternal education (elementary school, high school or technical school, university education, higher academic education, other education, or missing), maternal smoking (nonsmokers, or \< 5, \> 5 to 15, \> 15 cigarettes/day), maternal concentrations of cholesterol and triglycerides (millimoles per liter), child's birth weight (continuous), and child's sex. We considered gestational age to be a potential intermediate variable and therefore excluded it from the model. Information on maternal smoking and education was missing for 6% of participants, and 3.5% had missing information on maternal prepregnancy BMI. Complete information was available for the remaining covariates. Missing covariate values were substituted using multiple imputation (PROC MI) in SAS. We did not adjust for fish intake to avoid overadjusting our model ([@r16]).

All tests were two-sided and statistical significance was considered at *p* \< 0.05. All analyses were carried out using SAS statistical software (version 9.3; SAS Institute Inc., Cary, NC, USA).

Results
=======

Characteristics of the study population are shown in [Table 1](#t1){ref-type="table"}. The median maternal serum concentration from gestational week 30 was 1.37 ng/mL for PCB-153, 0.54 ng/mL for HCB, and 2.47 ng/mL for *p,p*´-DDE. Approximately 13% of the offspring had been prescribed asthma medications, whereas 14% had a self-reported lifetime diagnosis of asthma. The proportion of offspring with a hospital asthma diagnosis was 4%, whereas 7% had self-reported use of asthma medication in the previous 12 months ([Table 1](#t1){ref-type="table"}).

###### 

Maternal and offspring characteristics of 872 mother--child pairs.

  Characteristic                        Median (10th, 90th percentiles), mean ± SD, or *n* (%)
  ------------------------------------- --------------------------------------------------------
  Maternal                              
  Serum concentration (ng/mL)           
  PCB-118                               0.17 (0.09, 0.30)
  PCB-138                               0.74 (0.41, 1.25)
  PCB-153                               1.37 (0.76, 2.26)
  PCB-156                               0.10 (0.06, 0.16)
  PCB-170                               0.37 (0.21, 0.59)
  PCB-180                               0.67 (0.38, 1.10)
  Sum of PCBs (pmol/mL)                 9.23 (5.32, 15.11)
  HCB                                   0.54 (0.31, 0.87)
  *p,p*´-DDE                            2.47 (1.03, 5.66)
  Maternal age at birth (years)         29.0 ± 4.2
  Fish intake (g/day)                   19.3 ± 15.6
  Alcohol (g/day)                       2.9 ± 3.8
  Maternal cholesterol (mmol/L)         7.3 ± 1.3
  Maternal triglycerides (mmol/L)       2.4 ± 0.8
  Previous births                       
  0                                     500 (57.3)
  1                                     279 (32.0)
  ≥ 2                                   93 (10.7)
  Cigarettes/day during pregnancy       
  0                                     493 (56.5)
  \> 0--5                               99 (11.4)
  \> 5 to 15                            188 (21.6)
  \> 15                                 41 (4.7)
  Missing                               51 (5.9)
  Maternal education                    
  Elementary school                     103 (11.8)
  High school or technical school       207 (23.7)
  University                            296 (33.9)
  Higher academic                       125 (14.3)
  Other education                       89 (10.2)
  Missing                               52 (6.0)
  Prepregnancy BMI (kg/m^2^)            
  \< 18.5                               89 (10.2)
  18.5 to \< 25                         676 (77.5)
  25 to \< 30                           53 (6.1)
  \> 30                                 23 (2.6)
  Missing                               31 (3.6)
  Offspring                             
  Registry-based diagnoses (*n*= 872)   
  Asthma medication                     111 (12.7)
  Asthma hospitalization                32 (3.7)
  Self-reported diagnoses (*n*= 654)    
  Lifetime doctor diagnosis             89 (13.6)
  Current asthma medication use         48 (7.3)
  Birth weight (g)                      3493.7 ± 579.9
  Gestational age (days)                282.3 ± 11.8
  Boys                                  461 (52.9)
  Age at follow-up (years)              19.6 ± 0.49

Of those who reported ever being diagnosed with asthma by a doctor, 72% were also classified as cases based on the medication registry data; 76% of those classified as cases based on the medication registry data self-reported a diagnosis. Only 4% of those who were not classified as cases based on the medication registry data had a self-reported diagnosis, and only 3.5% of those who did not report a diagnosis were classified as cases based on the medication registry data. The agreement between the hospital diagnoses and the other outcomes was lower both for cases and noncases (20--31%) (data not shown).

Compared with mothers who had PCB concentrations in the first and second tertiles, mothers in the third tertile of PCB concentration were older (30.4 years of age vs. 27.6 and 29.1 in the first tertile and second tertile, respectively), had higher mean fish intake (20.6 g/day vs. 18.8 and 18.4), higher alcohol intake (3.4 g/day vs. 2.5 and 2.9), were more likely to be nulliparous (64.6% vs. 52.4 and 55.0), and had higher academic education (16.8% vs. 13.6 and 16.4) ([Table 2](#t2){ref-type="table"}). Similar associations were also observed across the tertiles of HCB and *p,p*´-DDE exposures. There was no difference in maternal prepregnancy BMI across PCB tertiles. However, for HCB and *p,p*´-DDE maternal prepregnancy BMI was higher in the third tertiles compared with the first tertile (22.1 kg/m^2^ vs. 21.0 and 21.8 vs. 20.9 for HCB and *p,p*´-DDE, respectively). Offspring of mothers in the third tertiles of PCB and HCB exposure had slightly shorter gestation (281 days) compared with offspring of mothers in the first (283 days) and second tertile (283 days). This difference was not observed across the *p,p*´-DDE tertiles. There was no difference in birth weight across any of the exposure tertiles. More boys than girls were born to mothers in the third tertile of PCB exposure (58.1% vs. 49.0% in the first tertile). For all four outcomes of asthma, there were higher numbers of asthma cases in the second and third tertiles of maternal PCB and HCB exposures compared to the first tertile.

###### 

Maternal and offspring characteristics of 872 mother--child pairs across tertiles of maternal PCB, HCB, and *p,p´*-DDE serum concentrations.

  Characteristic                                     1st tertile      2nd tertile      3rd tertile      *p*-Value^*a*^
  -------------------------------------------------- ---------------- ---------------- ---------------- ----------------
  PCB concentration (pmol/mL) (range)                1.4--7.7         7.7--11.1        11.1--80.6       
  Maternal                                                                                              
  Maternal age at birth (years)                      27.6 ± 4.1       29.1 ± 3.9       30.4 ± 4.2       \< 0.001
  Fish intake (g/day)                                18.8 ± 16.3      18.4 ± 13.4      20.6 ± 16.7      0.21
  Alcohol (g/day)                                    2.5 ± 3.7        2.9 ± 3.3        3.4 ± 4.2        0.01
  Previous births (% nulliparous)                    152 (52.4)       160 (55.0)       188 (64.6)       0.02
  Smoking during pregnancy (% no)                    157 (57.5)       182 (66.4)       154 (56.2)       0.09
  Maternal education (% higher academic)             37 (13.6)        42 (15.4)        46 (16.8)        0.02
  Prepregnancy BMI (kg/m^2^)                         21.5 ± 3.0       21.5 ± 3.1       21.3 ± 3.2       0.72
  Offspring                                                                                             
  Birth weight (g)                                   3514.8 ± 507.7   3503.3 ± 563.8   3462.7 ± 541.1   0.47
  Gestational age (days)                             283 ± 10.8       283 ± 12.2       281 ± 12.3       0.03
  Sex (% boys)                                       142 (49.0)       150 (51.6)       169 (58.1)       0.08
  Asthma medication (*n* cases)                      33               36               42               0.53
  Asthma hospital diagnoses (*n* cases)              8                12               12               0.60
  Self-reported diagnoses (*n* cases)                22               34               33               0.26
  Current self-reported medication use (*n* cases)   11               18               19               0.35
  HCB concentrations (ng/mL) (range)                 0.1--0.5         0.5--0.6         0.6--2.5         
  Maternal                                                                                              
  Maternal age at birth (years)                      28.0 ± 4.1       28.9 ± 3.8       30.2 ± 4.2       \< 0.001
  Fish intake (g/day)                                18.1 ± 14.5      19.5 ± 15.7      20.2 ± 16.3      0.24
  Alcohol (g/day)                                    2.6 ± 3.8        3.0 ± 3.5        3.2 ± 3.9        0.14
  Previous births (% nulliparous)                    140 (48.3)       168 (57.7)       192 (66.0)       \< 0.001
  Smoking during pregnancy (% no)                    162 (59.6)       162 (59.3)       169 (61.2)       0.64
  Maternal education (% higher academic)             36 (13.2)        44 (16.2)        45 (16.3)        0.22
  Prepregnancy BMI (kg/m^2^)                         21.0 ± 2.5       21.2 ± 2.4       22.1 ± 4.0       \< 0.001
  Offspring                                                                                             
  Birth weight (g)                                   3483.2 ± 503.1   3534.7 ± 534.8   3463.0 ± 572.8   0.25
  Gestational age (days)                             283 ± 11.7       283 ± 10.9       281 ± 12.8       0.04
  Sex (% boys)                                       147 (50.7)       155 (53.3)       159 (54.6)       0.63
  Asthma medication (*n* cases)                      28               35               48               0.04
  Asthma hospital diagnoses (*n* cases)              8                12               12               0.60
  Self-reported diagnoses (*n* cases)                20               34               35               0.07
  Current self-reported medication use (*n* cases)   6                20               22               0.01
  *p,p*´-DDE concentrations (ng/mL) (range)          0.2--1.9         1.9--3.2         3.3--38.8        
  Maternal                                                                                              
  Maternal age at birth (years)                      28.0 ± 4.2       28.8 ± 4.0       30.3 ± 4.1       \< 0.001
  Fish intake (g/day)                                19.1 ± 14.7      17.7 ± 14.4      20.9 ± 17.3      0.05
  Alcohol (g/day)                                    2.4 ± 3.2        3.1 ± 3.9        3.4 ± 4.1        0.01
  Previous births (% nulliparous)                    148 (51.0)       171 (58.8)       181 (62.2)       0.05
  Smoking during pregnancy (% no)                    162 (58.5)       174 (64.4)       157 (57.3)       0.59
  Maternal education (% higher academic)             35 (12.6)        38 (14.1)        52 (19.0)        0.03
  Prepregnancy BMI (kg/m^2^)                         20.9 ± 2.7       21.5 ± 2.9       21.8 ± 3.6       0.003
  Offspring                                                                                             
  Birth weight (g)                                   3499.9 ± 533.5   3494.7 ± 519.8   3486.6 ± 561.1   0.96
  Gestational age (days)                             283 ± 11.7       282 ± 11.8       282 ± 12.0       0.49
  Sex (% boys)                                       146 (50.3)       159 (54.6)       156 (53.6)       0.56
  Asthma medication (*n* cases)                      37               34               40               0.76
  Asthma hospital diagnoses (*n* cases)              10               11               11               0.97
  Self-reported diagnoses (*n* cases)                30               31               28               0.89
  Current self-reported medication use (*n* cases)   16               16               16               0.99

HCB exposure in the third tertile was significantly associated with asthma classified according to medication use in both unadjusted (HR = 1.78; 95% CI: 1.12, 2.84) and adjusted (HR = 1.92; 95% CI: 1.15, 3.21) models ([Table 3](#t3){ref-type="table"}). We found that for the dioxin-like PCB-118 and PCB-156 combined, HRs of asthma medication use increased across maternal tertiles of exposure. The association was strongest for maternal concentrations of PCB-118 with offspring asthma medication use after adjustment for covariates (third vs. first tertile 1.90; 95% CI: 1.12--3.23). Although there were no significant associations between maternal concentrations of the sum of all PCBs and the non-dioxin-like PCBs with asthma medication use, HRs were positive and increased with increasing tertiles of maternal exposure. There was no association between maternal concentrations of *p,p*´-DDE and offspring asthma medication. Overall, additional adjustment for gestational age did not alter any of the results (data not shown).

###### 

Associations between maternal PCBs, HCB, and *p,p´*-DDE serum concentrations and offspring asthma medication use after 20 years of follow-up (*n* = 872) \[HR^*a*^ (95% CI)\].

  POPs in tertiles (range)              Raw model           Adjusted model^*b*^
  ------------------------------------- ------------------- ---------------------
  PCB--118 (ng/mL)                                          
  1st (0.02--0.14)                      1.00                1.00
  2nd (\> 0.14--0.20)                   1.50 (0.92, 2.45)   1.60 (0.96, 2.66)
  3rd (\> 0.20--0.61)                   1.69 (1.05, 2.73)   1.90 (1.12, 3.23)
  *p* for trend^*c*^                    0.04                0.02
  PCB--156 (ng/mL)                                          
  1st (0.01--0.08)                      1.00                1.00
  2nd (\> 0.08--0.12)                   1.33 (0.82, 2.15)   1.38 (0.84, 2.26)
  3rd (\> 0.12--0.92)                   1.43 (0.90, 2.29)   1.45 (0.85, 2.46)
  *p* for trend^*c*^                    0.15                0.20
  Dioxin-like PCBs (pmol/mL)^*d*^                           
  1st (0.13--0.67)                      1.00                1.00
  2nd (\> 0.67--0.96)                   1.45 (0.90, 2.35)   1.56 (0.95, 2.56)
  3rd (\> 0.96--4.10)                   1.59 (0.99, 2.55)   1.75 (1.02, 2.98)
  *p* for trend^*c*^                    0.07                0.05
  Non-dioxin-like PCBs (pmol/mL)^*e*^                       
  1st (1.23--7.09)                      1.00                1.00
  2nd (\> 7.10--10.12)                  1.10 (0.69, 1.77)   1.15 (0.70, 1.86)
  3rd (\> 10.12--76.55)                 1.30 (0.83, 2.06)   1.30 (0.78, 2.17)
  *p* for trend^*c*^                    0.24                0.32
  Sum of all PCBs (pmol/mL)^*f*^                            
  1st (1.43--7.72)                      1.00                1.00
  2nd (\> 7.73--11.11)                  1.10 (0.68, 1.76)   1.15 (0.70, 1.87)
  3rd (\> 11.11--80.65)                 1.30 (0.83, 2.06)   1.30 (0.78, 2.17)
  *p* for trend^*c*^                    0.24                0.32
  HCB (ng/mL)                                               
  1st (0.07--0.45)                      1.00                1.00
  2nd (\> 0.45--0.63)                   1.26 (0.77, 2.07)   1.31 (0.79, 2.17)
  3rd (\> 0.63--2.45)                   1.78 (1.12, 2.84)   1.92 (1.15, 3.21)
  *p* for trend^*c*^                    0.01                0.01
  *p,p*´--DDE (ng/mL)                                       
  1st (0.20--1.86)                      1.00                1.00
  2nd (\> 1.86--3.24)                   0.91 (0.57, 1.44)   0.92 (0.5, 1.47)
  3rd (\> 3.25--38.77)                  1.09 (0.70, 1.71)   1.09 (0.67, 1.77)
  *p* for trend^*c*^                    0.62                0.64

In most cases, maternal concentrations of PCBs and HCB were positively associated with asthma hospital diagnoses, self-reported lifetime diagnoses, and self-reported current medication use ([Table 4](#t4){ref-type="table"}). The strongest associations were found between maternal concentrations and PCB-118 and HCB and self-reported current use of asthma medication. No association was observed between maternal concentrations of *p,p*´-DDE and any asthma outcomes.

###### 

Associations between maternal PCBs, HCB, and *p,p´*-DDE serum concentrations and the risk of offspring hospital diagnoses (*n* = 872), self-reported doctor diagnosis of asthma (*n* = 654), and self-reported current medication use (*n* = 654) in the adjusted model^*a*^.

  POPs in tertiles (range)              Asthma hospital diagnoses \[HR^*b*^ (95% CI) *n*= 872\]   Self-reported lifetime diagnosis \[Odds ratio^*c*^ (95% CI) *n*= 654\]   Current self-reported medication use \[Odds ratio^*c*^ (95% CI) *n*= 654\]
  ------------------------------------- --------------------------------------------------------- ------------------------------------------------------------------------ ----------------------------------------------------------------------------
  PCB-118 (ng/mL)                                                                                                                                                          
  1st (0.02--0.14)                      1.00                                                      1.00                                                                     1.00
  2nd (\> 0.14--0.20)                   0.85 (0.50, 1.46)                                         1.76 (0.94, 3.26)                                                        1.90 (0.80, 4.52)
  3rd (\> 0.20--0.61)                   1.31 (0.78, 2.20)                                         1.73 (0.90, 3.31)                                                        2.49 (1.03, 5.99)
  *p* for trend^*d*^                    0.32                                                      0.16                                                                     0.05
  PCB-156 (ng/mL)                                                                                                                                                          
  1st (0.01--0.08)                      1.00                                                      1.00                                                                     1.00
  2nd (\> 0.08--0.12)                   1.38 (0.85, 2.25)                                         1.52 (0.83, 2.80)                                                        1.75 (0.75, 4.07)
  3rd (\> 0.12--0.92)                   0.94 (0.53, 1.66)                                         1.41 (0.73, 2.71)                                                        2.01 (0.82, 4.93)
  *p* for trend^*d*^                    0.76                                                      0.38                                                                     0.15
  Dioxin-like PCBs (pmol/mL)^*e*^                                                                                                                                          
  1st (0.13--0.67)                      1.00                                                      1.00                                                                     1.00
  2nd (\> 0.67--0.96)                   1.36 (0.84, 2.21)                                         1.83 (1.00, 3.36)                                                        1.80 (0.79, 4.11)
  3rd (\> 0.96--4.10)                   1.00 (0.57, 1.75)                                         1.45 (0.75, 2.83)                                                        1.90 (0.79, 4.59)
  *p* for trend^*d*^                    0.40                                                      0.40                                                                     0.19
  Non-dioxin-like PCBs (pmol/mL)^*f*^                                                                                                                                      
  1st (1.23--7.09)                      1.00                                                      1.00                                                                     1.00
  2nd (\> 7.10--10.12)                  1.01 (0.61, 1.68)                                         1.40 (0.77, 2.56)                                                        1.35 (0.60, 3.00)
  3rd (\> 10.12--76.55)                 1.19 (0.69, 2.04)                                         1.27 (0.67, 2.44)                                                        1.48 (0.63, 3.46)
  *p* for trend^*d*^                    0.40                                                      0.57                                                                     0.39
  Sum of all PCBs (pmol/mL)^*g*^                                                                                                                                           
  1st (1.43--7.72)                      1.00                                                      1.00                                                                     1.00
  2nd (\> 7.73--11.11)                  1.12 (0.68, 1.84)                                         1.59 (0.87, 2.90)                                                        1.59 (0.71, 3.60)
  3rd (\> 11.11--80.65)                 1.22 (0.71, 2.09)                                         1.30 (0.67, 2.51)                                                        1.63 (0.68, 3.88)
  *p* for trend^*d*^                    0.30                                                      0.59                                                                     0.32
  HCB (ng/mL)                                                                                                                                                              
  1st (0.07--0.45)                      1.00                                                      1.00                                                                     1.00
  2nd (\> 0.45--0.63)                   1.66 (0.66, 4.13)                                         1.79 (0.97, 3.31)                                                        3.38 (1.29, 8.85)
  3rd (\> 0.63--2.45)                   1.84 (0.70, 4.86)                                         1.85 (0.97, 3.51)                                                        4.18 (1.57, 11.15)
  *p* for trend^*d*^                    0.24                                                      0.09                                                                     0.01
  *p,p*´--DDE (ng/mL)                                                                                                                                                      
  1st (0.20--1.86)                      1.00                                                      1.00                                                                     1.00
  2nd (\> 1.86--3.24)                   1.17 (0.49, 2.80)                                         0.96 (0.55, 1.69)                                                        0.95 (0.45, 1.98)
  3rd (\> 3.24--38.77)                  1.14 (0.46, 2.85)                                         0.80 (0.44, 1.45)                                                        0.86 (0.40, 1.85)
  *p* for trend^*d*^                    0.80                                                      0.48                                                                     0.91

The correlations between the compounds were high (Spearman *r* = 0.53--0.99), which made mutual adjustments problematic. However, when the analyses with PCB-118 and HCB (Spearman *r* = 0.77) were mutually adjusted for each other in addition to the other covariates, we found weakened associations and wider CIs for PCB-118 (HR = 1.47; 95% CI: 0.75, 2.86) and for HCB (HR = 1.58; 95% CI: 0.83, 3.01) with offspring asthma medication use comparing the third tertile to the first tertile of exposure (data not shown).

Discussion
==========

In this study with 20 years of follow-up we observed positive associations between maternal serum concentrations of PCBs and HCB and offspring use of asthma medications. For the PCBs, the strongest associations were found for the dioxin-like PCB-118. Similar associations were observed when we used three additional asthma outcomes, including hospital diagnoses and self-reported diagnoses. No associations were found for maternal concentrations of *p,p*´-DDE and offspring asthma.

To our knowledge, only a few studies have examined developmental exposures to PCBs in relation to wheezing and asthma, and their results have varied, with some reporting positive associations ([@r14]; [@r42]), whereas another reported an inverse association ([@r49], [@r50]). In contrast with these studies, we also estimated associations with specific PCB congeners, in addition to the sum of all quantified PCBs. Of the six quantified PCB congeners, only dioxin-like PCB-118 was significantly associated with offspring asthma, and a stronger association was observed for the two dioxin-like congeners combined (PCBs 118 and 156) compared with the non-dioxin-like congeners (PCBs 138, 153, 170, and 180) and the sum of all PCBs.

The suspected influence of the dioxin-like PCBs on immunoregulation is, at least partly, thought to be related to interactions with the aryl hydrocarbon receptor (AhR). AhR-mediated responses with dioxin and dioxin-like compounds are thought to contribute to asthma pathogenesis through increased expression of inflammatory cytokines, including tumor necrosis factor-α and interleukin-1β, which in turn can induce mucin production, cell chemotaxis, and immunoglobulin E (IgE) production ([@r6]). Whether AhR-mediated responses are relevant to effects of developmental exposures to dioxin-like PCBs is unclear. Stronger associations of PCB-118 with asthma in our study are also indirectly supported by two studies. PCB-118 was positively associated with cord IgE concentrations in a cross-sectional study of children from the Slovak Republic, but no associations were reported for the other quantified PCB congeners ([@r40]). In an *in vitro* study, treatment with PCB-118, but not PCB-153, led to a shift in the differentiation of CD4^+^ T lymphocytes toward a T-helper 2--dominated response, which is consistent with allergic disease ([@r12]).

We are not aware of previous studies specifically designed to examine developmental HCB exposures and the risk of offspring asthma. HCB was not associated with wheezing or asthma in a cross-sectional study of 124 Japanese adults ([@r28]), but HCB has been found to induce airway hyperreactivity in tissue from HCB-exposed Brown Norway rats (Michielsen C et al. 2002; Michielsen CP et al. 2001). HCB has also been reported to show some agonist activity with the AhR ([@r46]), which suggests that HCB might affect the immune system and asthma through AhR-mediated mechanisms.

In contrast to two previous studies ([@r22]; [@r43]), we did not find any associations between maternal concentrations of *p,p*´-DDE and offspring asthma. It is worth noting that the children in the previous studies were younger (4--9 years of age) than our study population, and their findings may therefore at least partly reflect associations with wheezing symptoms that often resolve later in childhood ([@r2]; [@r19]; [@r44]).

Breastfeeding may play an important role on the development of the infant's immune system ([@r3]). On the other hand, breastfeeding is also a major source of exposure to PCBs and other lipophilic pollutants during the first year of life, with accumulation that is proportional to maternal concentrations ([@r48]) and the duration of breastfeeding ([@r36]). In a study of prenatal and lactational exposures to PCBs in a relatively highly exposed fishing community ([@r14]), duration of breastfeeding was strongly correlated with offspring IgE concentrations at 7 years of age, whereas only a nonsignificant positive association was observed for prenatal PCB exposures. Although the focus of that study was on allergic sensitization and not asthma, the results support the potential importance of lactational POP exposures to immunoregulation. Absence of information on breastfeeding in our study is therefore a major limitation. As a result, we therefore cannot determine to which degree the associations observed in our study may be related to *in utero* exposure, lactational exposures, or a combination of both. Although speculative, previous surveys suggest that most children in Denmark were exclusively breastfed during the study's time period ([@r47]), which may possibly reduce potential confounding by breastfeeding.

The long prospective follow-up period and the high inclusion of 90% (872/965) of the offspring of women originally enrolled in the cohort are major strengths of our study. In contrast to previous studies that have mostly relied on self-reported asthma, our outcome measure was based on objective register data, where misclassification of ICD-10 asthma diagnoses has been shown to be low ([@r34]). A possible limitation of the definition of asthma based on medication data is that medicine may have been prescribed to clarify a diagnosis, and this method may therefore overestimate the true prevalence of disease; however, we used a definition based on medication data that has been validated against medical records with a sensitivity of 63% and specificity of 86% compared with a doctor diagnosis of asthma ([@r30]). Furthermore, we did not consider prescriptions before 6 years of age, which we believe is a strength because many children are prescribed asthma medications in the first years of life, although they do not necessarily develop clinical asthma ([@r20]). In most analyses with PCBs and HCB, we observed positive associations with the outcomes. The analyses based on the hospital diagnoses and the self-reported diagnoses of asthma did not always reach statistical significance, possibly due to a small number of cases and fewer subjects in the analyses, respectively. The significant associations observed between PCB-118 and HCB and self-reported current use of asthma medication may suggest that the associations are driven by persistent cases of asthma that require continuous medical treatment at 20 years of age.

As in any other observational study, we cannot exclude the possibility that the observed associations were influenced by residual or unmeasured confounding, including breastfeeding. The POPs included in our study were highly correlated, and consequently we could not distinguish the contributions of individual compounds to the observed associations. The potential confounders that we included as adjustment factors in our regression models seemed to influence our results to a minimal degree, suggesting limited residual confounding.

In conclusion, this study provides epidemiologic evidence that maternal concentrations of dioxin-like PCBs and HCB may be associated with the offspring's risk of developing asthma that persists into adulthood. However, we cannot exclude the possibility that these associations may be mediated through postnatal exposures to POPs. Our results provide support for the hypothesis that early-life exposure to POPs may have immunoregulatory effects. Although the concentrations of these particular environmental contaminants have generally decreased since the late 1980s, industrial reduction in production and usage of one particular class of contaminants has typically been matched with a corresponding rise in the production and usage of other related industrial chemicals ([@r11]; [@r17]) that have been less extensively studied with respect to potential health effects. In addition, evidence regarding the potential health effects of POPs will continue to be relevant to populations with high risks of occupational exposures ([@r41]) and to communities with high consumption of fish and other marine species ([@r4]).
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